The estimated Net Worth of David A Ford is at least $2.27 Million dollars as of 9 April 2020. Mr. Ford owns over 58 units of Intercept Pharmaceuticals Inc stock worth over $263,758 and over the last 8 years he sold ICPT stock worth over $94,464. In addition, he makes $1,912,650 as Chief Human Resource Officer at Intercept Pharmaceuticals Inc.
David has made over 4 trades of the Intercept Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 58 units of ICPT stock worth $4,060 on 9 April 2020.
The largest trade he's ever made was selling 800 units of Intercept Pharmaceuticals Inc stock on 16 September 2019 worth over $56,000. On average, David trades about 31 units every 5 days since 2017. As of 9 April 2020 he still owns at least 13,882 units of Intercept Pharmaceuticals Inc stock.
You can see the complete history of Mr. Ford stock trades at the bottom of the page.
David A. Ford serves as Chief Human Resource Officer of the Company. He brings over 25 years of experience in a variety of human resources roles across the United States, Europe, Latin America and New Zealand. Prior to joining the Company, Mr. Ford spent nearly 15 years at Sanofi, where he most recently served as Vice President Human Resources for the Sanofi Genzyme global business unit from January 2016 to May 2017. Prior to that role, from November 2011 through December 2015, Mr. Ford served as Vice President Human Resources for the Sanofi North American businesses. Mr. Ford joined the pharmaceutical industry in 2002 as the HR Director—United Kingdom and Republic of Ireland for Sanofi-Synthelabo. Mr. Ford holds a master’s degree in business administration from INSEAD, Fontainebleau (France).
As the Chief Human Resource Officer of Intercept Pharmaceuticals Inc, the total compensation of David Ford at Intercept Pharmaceuticals Inc is $1,912,650. There are 7 executives at Intercept Pharmaceuticals Inc getting paid more, with Mark Pruzanski having the highest compensation of $6,615,780.
David Ford is 51, he's been the Chief Human Resource Officer of Intercept Pharmaceuticals Inc since 2017. There are 16 older and 5 younger executives at Intercept Pharmaceuticals Inc. The oldest executive at Intercept Pharmaceuticals Inc is Keith Gottesdiener, 66, who is the Independent Director.
David's mailing address filed with the SEC is C/O PROTHENA BIOSCIENCES INC, 1800 SIERRA POINT PARKWAY, BRISBANE, CA, 94005.
Over the last 12 years, insiders at Intercept Pharmaceuticals Inc have traded over $1,530,243,701 worth of Intercept Pharmaceuticals Inc stock and bought 2,408,920 units worth $77,118,364 . The most active insiders traders include Srinivas Akkaraju, Jonathan Silverstein, and Francesco Micheli. On average, Intercept Pharmaceuticals Inc executives and independent directors trade stock every 10 days with the average trade being worth of $1,114,673. The most recent stock trade was executed by Srinivas Akkaraju on 10 March 2021, trading 237,000 units of ICPT stock currently worth $5,017,290.
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Intercept Pharmaceuticals Inc executives and other stock owners filed with the SEC include: